The value of vedolizumab as rescue therapy in moderate-severe Crohn's disease patients with adalimumab non-response in the USA

DO Erim; N Mahendraratnam; PN Okafor; SB Wheeler

doi:doi:10.1093/ecco-jcc/jjv090

RTI uses cookies to offer you the best experience online. By and clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.

Accept

The value of vedolizumab as rescue therapy in moderate-severe Crohn's disease patients with adalimumab non-response in the USA

Erim, DO., Mahendraratnam, N., Okafor, PN., & Wheeler, SB. (2015). The value of vedolizumab as rescue therapy in moderate-severe Crohn's disease patients with adalimumab non-response in the USA. Journal of Crohn's and Colitis. https://doi.org/10.1093/ecco-jcc/jjv090

Copy citation

Recent Publications

OCCASIONAL PAPER

Does the relationship between alcohol retail environment and alcohol outcomes vary by depressive symptoms? Findings from a US Survey of Black, Hispanic and White drinkers

The value of vedolizumab as rescue therapy in moderate-severe Crohn's disease patients with adalimumab non-response in the USA

Publications Info

Recent Publications

Bringing an equity-centered framework to research

The Preschool Entitlement

Culturally informed community engagement

Does the relationship between alcohol retail environment and alcohol outcomes vary by depressive symptoms? Findings from a US Survey of Black, Hispanic and White drinkers

Partner With Us

Site